Evidence map›Paper›PMID 31006917›Full record

ArticleMolecular carcinogenesis2019

Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice.

Sharad S Singhal, David Horne, Jyotsana Singhal, Steven Vonderfecht, Ravi Salgia, Sanjay Awasthi

Open access · greenAbstract read
In one paragraph

Article in Molecular carcinogenesis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Frontiers in immunology · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. 2'-Hydroxyflavanone prevents LPS-induced inflammatory response and cytotoxicity in murine macrophages.Toxicology in vitro : an international journal published in association with BIBRA · 2020
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sharad S SinghalDepartments of Medical Oncology, City of Hope National Medical Center and Comprehensive Cancer Center, Duarte, California.ORCID 0000-0002-6415-8160
David HorneMolecular Medicine, City of Hope National Medical Center and Comprehensive Cancer Center, Duarte, California.
Jyotsana SinghalDepartments of Medical Oncology, City of Hope National Medical Center and Comprehensive Cancer Center, Duarte, California.
Steven VonderfechtPathology Core, City of Hope National Medical Center and Comprehensive Cancer Center, Duarte, California.
Ravi SalgiaDepartments of Medical Oncology, City of Hope National Medical Center and Comprehensive Cancer Center, Duarte, California.
Sanjay AwasthiDepartment of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas.
City Of Hope National Medical Center · USTexas Tech University · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
MECHANISM OF DRUG TRANSPORT IN LUNG CANCER CELLSR01CA077495 · NCI · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI AWASTHI, SANJAY · 1998 to 2011
$2.8M
NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA077495
6 · The paper itself

Abstract

Substantial evidence suggests that 7,12-dimethylbenzanthracene (DMBA)-induced mammary carcinogenesis in mice mimics human breast cancer (BC) in many respects. Therefore, it has been used extensively to evaluate preventive and therapeutic agents for human BC. Mammary carcinogenesis induced by DMBA administration in female SENsitive to CARcinogen (SENCAR) mice was characterized by histopathological analysis of the mammary glands and alterations to the phosphatidylinositol 3-kinase/protein kinase B/cyclin-dependent kinase 1 (PI3K/Akt/CDK1) pathway. We recently reported that 2'-hydroxyflavanone (2HF) is a promising diet-derived chemotherapeutic agent that suppresses BC growth in vitro and in vivo by targeting a 76 kDa ral-interacting protein (RLIP). The objective of the current study was to investigate the synergistic anticarcinogenic effects of RLIP inhibition/depletion and 2HF in an in vivo model of DMBA-induced mammary carcinogenesis in SENCAR mice. Mice were given 2HF (50 mg/kg, bw, orally on alternate days), RLIP antibody (Rab; 5 mg/kg, bw, ip weekly), RLIP antisense (RAS; 5 mg/kg, b.w., ip weekly), or a combination of 2HF + Rab + RAS. Animals were monitored daily, and 7 days after the first appearance of moribund behavior, tissues were harvested for morphological and immunohistological analysis. Western blot analyses were performed to determine the expression of anti- and proapoptotic proteins in the mammary glands. Our results reveal that 2HF, RAS, and Rab significantly prevented the carcinogenic effects of DMBA administration in the mammary glands and other organs. Further, mice treated with a combination of 2HF + RAS + Rab exhibited no carcinogenic effect of DMBA as compared to either or the single agent-treated mice. This study demonstrates for the first time the anticarcinogenic effects of 2HF and RLIP inhibition/depletion in vivo in a novel DMBA-induced model of BC in SENCAR mice and provides the rationale for further clinical investigation.

Indexed as

9,10-Dimethyl-1,2-benzanthraceneAnimalsAnticarcinogenic AgentsCDC2 Protein KinaseCell Transformation, NeoplasticDisease Models, AnimalFemaleFlavanonesGTPase-Activating ProteinsMammary Glands, AnimalMammary Neoplasms, ExperimentalMiceMice, Inbred SENCARPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akt2'-hydroxyflavanone9,10-Dimethyl-1,2-benzanthraceneAnticarcinogenic AgentsCDC2 Protein KinaseCdk1 protein, mouseFlavanonesGTPase-Activating ProteinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRalbp1 protein, mousechemotherapeuticsDMBAmammary glandmercapturic acid pathway transporterphytochemicalsRLIP

Identifiers

PMID31006917
PMCPMC8742507
OpenAlexW2940968022

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.